Abstract: The present disclosure provides therapeutic agents comprising VLA-4 (a4b1) and a4b?inhibiting agents defined herein. Methods of using the therapeutic agents are also provided. The present disclosure further provides combinations of a VLA-4 inhibitor and one or more agents which interact with a chemokine receptor or chemokine receptors, and methods of use thereof. In some embodiments, the disclosed combinations may be used in a method of mobilizing hematopoietic stem cells. In some embodiments, the disclosed methods may be used in the treatment of a condition that requires the collection of hematopoietic stem cells for transfusions or in chemotherapy. The present disclosure further provides methods of treating a patient comprising administering an agent which interacts with a chemokine such as G-CSF, plerixafor, BL-8040 (Motixafortide), or Crop and VLA-4 inhibitors.

Abstract: Described herein are methods and systems for processing a biological sample of a subject to determine whether the subject has or is at an increased risk of developing a disease or disorder. Methods of the present disclosure may be performed using a trained machine learning algorithm to predict disease or risk of disease, identify disease, or monitor disease. Methods may be performed using a nuclear magnetic resonance (NMR) spectrum of a subject or a metabolome of the subject. Methods may predict, identify, or monitor diseases such as cancers, metabolic diseases or disorders, inflammatory diseases or disorders, or neurological diseases or disorders. Methods may be performed using a cloud computing system. Methods may provide a report to the subject indicating whether the subject has or is at an increased risk of developing a disease or disorder.

Abstract: The present disclosure provides therapeutic agents including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such therapeutic agents. Methods of using the therapeutic agents are also provided. The present disclosure further provides combinations of a VLA-4 inhibitor and an agent which interacts with a chemokine receptor, and methods of use thereof. In some embodiments, the disclosed combinations may be used in a method of mobilizing hematopoietic stem cells. In some embodiments, the disclosed methods may be used in the treatment of a condition which requires the collection of hematopoietic stem cells for transfusions or in chemotherapy. The present disclosure further provides methods of treating a patient comprising administering an agent which interacts with a chemokine such as G-CSF, plerixafor, or Gro-? and VLA-4 inhibitors.